JNJ-63723283
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for JNJ-63723283, covering 2019-11-12 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers [Phase 1, Phase 2]